Dr. Shaji Kumar on Upfront Combination Treatments in Multiple Myeloma

Video

​Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the impact of combination treatments upfront in multiple myeloma.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the impact of combination treatments upfront in multiple myeloma.

Using several novel agents in combination upfront— such as bortezomib, lenalidomide, and dexamethasone—has been shown to improve survival. Other triplet combinations, such as carfilzomib-lenalidomide-dexamethasone have also shown promise in multiple myeloma.

These triplet combinations make it more likely that a patient will experience a deep response, and in turn experience longer overall survival (OS), said Kumar. Even if they do not experience longer OS, progression-free survival (PFS) may be improved with a triplet combination, which can improve quality of life, he said.

Often, patients can not go back on a drug once they have progressed on it, but the data that is available right now suggests that the benefit patients get by combining different classes of drugs in the upfront setting is worth the drug not being available to them later on.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,